Nicox announced the submission of a New Drug Application (NDA) to the FDA for approval of AC 170, its novel...
AC Immune SA announced that its partner Genentech, a member of Roche group, has decided to start a second Phase...
Sorrento Therapeutics received clearance from the FDA to initiate a Phase II trial of AC 0010MA (abivertinib) in patients with COVID-19 who have moderate to severe pulmonary symptoms.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 8 to 3 against approving an NDA for AC 220 (quizartinib), from...
Daiichi Sankyo announced that the FDA has extended the review period for the New Drug Application (NDA) of AC 220...
Objectives: To establish a novel approach to classify fibrinogen disorders, we investigated the potential of clot waveform analysis (CWA) of CFA and searched for a surrogate marker for fibrinogen Ag.
Daiichi Sankyo announced updated positive results from the pivotal QuANTUM-R phase III study of AC 220 (quizartinib) which showed that...
AC Immune SA announced that Genentech, a member of the Roche Group, has informed the Company of top line results from a Phase II trial of the anti-Tau antibody, semorinemab, in early (prodromal to mild) Alzheimer’s disease (AD) which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo.
Daiichi Sankyo announced comprehensive analyses of overall survival from the pivotal QuANTUM-R phase III study of single agent AC 220...
The purpose of this study was to compare topical olopatadine and ketotifen in terms of effectiveness and safety for the management of AC.